Former Bristol-Myers Squibb man becomes head of Savient Europe
pharmafile | January 18, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â BMS, SavientÂ
Savient Pharmaceuticals has appointed David Veitch as the new president of its European division.
Veitch joins the specialist biopharma firm with over 24 years of pharma experience at Bristol-Myers Squibb and formerly SmithKline Beecham.
Most recently he served as senior vice president of European marketing and brand commercialisation at BMS. Prior to that, Veitch spent ten years serving in a number of leadership positions at the US firm.
He received his Bachelor of Science degree from Bristol University, England.
He will report directly to John Johnson, chief executive and president of Savient, and will be responsible for establishing, building and leading Savient’s European regional organisation to launch its gout drug Krystexxa.
Related Content

Elekta and BMS partner for digital treatment for melanoma
Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan …

BMS acquires Mirati Therapeutics for $4.8bn
Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a …

BMS shares new research and development  plans at the company’s R&D day
Bristol Myers Squibb (BMS) recently held a Research and Development (R&D) Day in New York, …






